Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1 asset
Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1……
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D…
Lucid Diligence Brief: InSilico Medicine and Lilly global partnership
Lucid Diligence Brief: InSilico Medicine and Lilly global partnership…
Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics
Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics Professional…
Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in COPD
Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in……
Lucid Diligence Brief: Pinnacle Medicines $89 million Series B
Lucid Diligence Brief: Pinnacle Medicines $89 million Series B Professional…
Lucid Diligence Brief: MSD to acquire Terns
Lucid Diligence Brief: MSD to acquire Terns Professional audiences only. Not…
Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery…
Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines
Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines Professional…
Lucid Diligence Brief: Dizal announces Zegfrovy (sunvozertinib) positive results in EGFR Exon20ins NSCLC
Lucid Diligence Brief: Dizal announces Zegfrovy (sunvozertinib) positive…
Lucid Diligence Brief: Fauna Bio obesity target designation with Lilly
Lucid Diligence Brief: Fauna Bio obesity target designation with Lilly…
Lucid Diligence Brief: Novartis to acquire Pikavation Therapeutics from Synnovation
Lucid Diligence Brief: Novartis to acquire Pikavation Therapeutics from…